{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:26:13Z","timestamp":1791559573002,"version":"4.3.4"},"reference-count":25,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.26023","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:11:10Z","timestamp":1787955070000},"page":"238-243","source":"Crossref","is-referenced-by-count":1,"title":["A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression"],"prefix":"10.3960","volume":"66","author":[{"given":"Ai","family":"Takahara","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kanemasa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Kuga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Ishimine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Sawabe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mano","family":"Mino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Okuya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kusuhara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunekazu","family":"Hishima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 384: 842-858.","DOI":"10.1056\/NEJMra2027612"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Tilly H, Morschhauser F, Sehn LH <i>et al.<\/i> Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 386: 351-363.","DOI":"10.1056\/NEJMoa2115304"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Thieblemont C, Phillips T, Ghesquieres H <i>et al.<\/i> Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial. J Clin Oncol. 2023; 41: 2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy. Lancet Oncol. 2020; 21: e463-e476.","DOI":"10.1016\/S1470-2045(20)30328-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Borcoman E, Kanjanapan Y, Champiat S <i>et al.<\/i> Novel patterns of response under immunotherapy. Ann Oncol. 2019; 30: 385-396.","DOI":"10.1093\/annonc\/mdz003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Chanan-Khan A, Miller KC, Lawrence D <i>et al.<\/i> Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011; 117: 2127-2135.","DOI":"10.1002\/cncr.25748"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Sortais C, Cordeil S, Bourbon E <i>et al.<\/i> Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas. Leuk Lymphoma. 2023; 64: 707-711.","DOI":"10.1080\/10428194.2022.2161304"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Imataki O, Uemura M, Fujita H, Kadowaki N. Pathological landscape of tumor flare reaction to epcoritamab treatment. Int J Hematol. 2024; 120: 467-471.","DOI":"10.1007\/s12185-024-03833-w"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Fujita M, Okamoto S, Jinnouchi K <i>et al.<\/i> Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction. Int J Hematol. 2025; 122: 148-152.","DOI":"10.1007\/s12185-025-03979-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Imataki O, Uchida S, Uemura M. Metabolic pitfall of pseudoprogression after epcoritamab treatment. EJHaem. 2024; 5: 1346-1347.","DOI":"10.1002\/jha2.1026"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 de Miguel M, Calvo E. Clinical Challenges of Immune Checkpoint Inhibitors. Cancer Cell. 2020; 38: 326-333.","DOI":"10.1016\/j.ccell.2020.07.004"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Chanan-Khan AA, Chitta K, Ersing N <i>et al.<\/i> Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011; 155: 457-467.","DOI":"10.1111\/j.1365-2141.2011.08882.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008; 26: 1544-1552.","DOI":"10.1200\/JCO.2007.14.5367"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Aue G, Njuguna N, Tian X <i>et al.<\/i> Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009; 94: 1266-1273.","DOI":"10.3324\/haematol.2009.005835"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Danylesko I, Shouval R, Shem-Tov N <i>et al.<\/i> Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplant. 2021; 56: 1134-1143.","DOI":"10.1038\/s41409-020-01156-y"},{"key":"16","unstructured":"16 Tepkinly: EPAR - Product information from European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tepkinly-epar-product-information_en.pdf."},{"key":"17","unstructured":"17 Columvi (glofitamab) Healthcare Professional Guide from Roche. https:\/\/assets.hpra.ie\/products\/Human\/39260\/f789c765-864b-424c-aa55-c7e2c1249c2c.pdf."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Lee JH, Long GV, Menzies AM <i>et al.<\/i> Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol. 2018; 4: 717-721.","DOI":"10.1001\/jamaoncol.2017.5332"},{"key":"19","unstructured":"19 Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019; 9: 1546-1553."},{"key":"20","unstructured":"20 Xaubet A, Diumenjo MC, Ma\u0155in A <i>et al.<\/i> Characteristics and prognostic value of pleural effusions in non-Hodgkin\u2019s lymphomas. Eur J Respir Dis. 1985; 66: 135-140."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Li J, Zhao S, Zhang W <i>et al.<\/i> Serous Effusions Diagnostic Accuracy for Hematopoietic Malignancies: A Cyto-Histological Correlation. Front Med (Lausanne). 2020; 7: 615080.","DOI":"10.3389\/fmed.2020.615080"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Li T, Gibiansky L, Parikh A <i>et al.<\/i> Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma. Clin Pharmacol Ther. 2025; 117: 1437-1450.","DOI":"10.1002\/cpt.3588"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Birtas Atesoglu E, Gulbas Z, Uzay A <i>et al.<\/i> Glofitamab in relapsed\/refractory diffuse large B-cell lymphoma: Real-world data. Hematol Oncol. 2023; 41: 663-673.","DOI":"10.1002\/hon.3174"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Won SE, Park HJ, Byun S <i>et al.<\/i> Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Oncoimmunology. 2020; 9: 1776058.","DOI":"10.1080\/2162402X.2020.1776058"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Cheson BD, Ansell S, Schwartz L <i>et al.<\/i> Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016; 128: 2489-2496.","DOI":"10.1182\/blood-2016-05-718528"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/3\/66_26023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:34:50Z","timestamp":1791005690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/3\/66_26023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.26023","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26023"}}